These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 8796144

  • 1. Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas.
    Aguiar RC, Dahia PL, Sill H, Toledo SP, Goldman JM, Cross NC.
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):93-6. PubMed ID: 8796144
    [Abstract] [Full Text] [Related]

  • 2. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F.
    Oncogene; 2001 Nov 08; 20(51):7573-7. PubMed ID: 11709729
    [Abstract] [Full Text] [Related]

  • 3. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A, Gaddipati JP, Moul JW, Srivastava S.
    J Urol; 1998 May 08; 159(5):1725-30. PubMed ID: 9554401
    [Abstract] [Full Text] [Related]

  • 4. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
    Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pullan PT, Hammond J, Marsh DJ, Robinson BG.
    Oncogene; 2003 Mar 06; 22(9):1358-64. PubMed ID: 12618761
    [Abstract] [Full Text] [Related]

  • 5. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
    Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu DB, Leggett B.
    Hepatology; 1997 Mar 06; 25(3):593-7. PubMed ID: 9049204
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
    Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T, Miyajima K, Iwamoto Y, Tsuneyoshi M.
    J Pathol; 2003 Nov 06; 201(3):487-95. PubMed ID: 14595762
    [Abstract] [Full Text] [Related]

  • 7. Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas.
    Hrasćan R, Pećina-Slaus N, Martić TN, Colić JF, Gall-Troselj K, Pavelić K, Karapandza N.
    J Neuroendocrinol; 2008 Aug 06; 20(8):1015-22. PubMed ID: 18510707
    [Abstract] [Full Text] [Related]

  • 8. p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan.
    Mangold KA, Takahashi H, Brandigi C, Wada T, Wakui S, Furusato M, Boyd J, Chandler FW, Allsbrook WC.
    J Urol; 1997 Mar 06; 157(3):1117-20. PubMed ID: 9072554
    [Abstract] [Full Text] [Related]

  • 9. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas.
    Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Chella A, Carnicelli V, Tognoni V, Filardo A, Angeletti CA, Bevilacqua G.
    J Pathol; 1997 Feb 06; 181(2):178-82. PubMed ID: 9120722
    [Abstract] [Full Text] [Related]

  • 10. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
    Schmid M, Malicki D, Nobori T, Rosenbach MD, Campbell K, Carson DA, Carrera CJ.
    Oncogene; 1998 Nov 19; 17(20):2669-75. PubMed ID: 9840931
    [Abstract] [Full Text] [Related]

  • 11. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN.
    J Neuropathol Exp Neurol; 1996 Oct 19; 55(10):1026-31. PubMed ID: 8857999
    [Abstract] [Full Text] [Related]

  • 12. Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor alpha complex, in sporadic phaeochromocytomas.
    Dahia PL, Toledo SP, Mulligan LM, Maher ER, Grossman AB, Eng C.
    Cancer Res; 1997 Jan 15; 57(2):310-3. PubMed ID: 9000574
    [Abstract] [Full Text] [Related]

  • 13. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
    García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, Bertino JR, Meyers P, Gorlick R.
    Clin Cancer Res; 2002 Mar 15; 8(3):782-7. PubMed ID: 11895909
    [Abstract] [Full Text] [Related]

  • 14. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status.
    Chaussade L, Eymin B, Brambilla E, Gazzeri S.
    Oncogene; 2001 Oct 04; 20(45):6587-96. PubMed ID: 11641784
    [Abstract] [Full Text] [Related]

  • 15. High prevalence of p16 genetic alterations in head and neck tumours.
    Miracca EC, Kowalski LP, Nagai MA.
    Br J Cancer; 1999 Oct 04; 81(4):677-83. PubMed ID: 10574255
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC.
    Oncogene; 1998 Nov 26; 17(21):2779-85. PubMed ID: 9840942
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.